Literature DB >> 9101640

Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro.

J Dürig1, T Bruhn, K H Zurborn, K Gutensohn, H D Bruhn, L Béress.   

Abstract

Anticoagulant fucoidan fractions of different molecular weight and sulfate content were prepared and investigated for their effects on platelet function in vitro. The fucoidan fractions were incubated with human platelet rich plasma (PRP) at concentrations of 5, 10 and 50 micrograms/ml. Platelet activation was subsequently studied by a standard aggregation assay and flow cytometric determination of the activation dependent platelet-surface markers CD62p (P-selectin, GMP-140) and CD63 (GP53). All fucoidan fractions induced irreversible platelet aggregation in a dose-dependent manner. Comparing fractions of identical molecular weight (100 kDa) the low sulfate content fucoidan FF5 (S = 7.6%) exerted a significantly greater effect than the highly sulfated fucoidan FF7 (S = 10.2%) over the whole concentration range (n = 5, P < 0.05). Among fractions of identical sulfate content fucoidan-induced platelet aggregation was also found to depend on the molecular weight of the fucoidan. At concentrations of 10 and 50 micrograms/ml the high molecular weight fraction FF7/1 (150 kDa) showed a significantly greater effect than the 50 kDa fraction FF7/3 (24.8 +/- 6.7 vs. 7.0 +/- 3.5 and 54.6 +/- 13.5 vs. 15.0 +/- 9.0%, respectively; mean +/- SD, n = 5, P < 0.05). The molecular weight dependence of the fucoidan effect was also reflected by the flow cytometric data. Coincubation of FF7/1 and FF7/3 (10 micrograms/ml) with PRP increased the number of CD62p and CD63 positive platelets by 9.0 +/- 3.3 vs. 2 +/- 1.9 and 7.1 +/- 2.4 vs. 3.2 +/- 2.6% over control values, respectively (n = 5, P < 0.05). In conclusion, our results show that the low molecular weight fucoidan FF7/3 combines potent anticoagulant and fibrinolytic properties with only minor platelet activating effects and is therefore a suitable substance for further pharmacological studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101640     DOI: 10.1016/s0049-3848(97)00037-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

1.  Fucoidan induces cancer cell apoptosis by modulating the endoplasmic reticulum stress cascades.

Authors:  Shaohua Chen; Yang Zhao; Yu Zhang; Daohai Zhang
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

Review 2.  MAPK signaling pathway-targeted marine compounds in cancer therapy.

Authors:  Jiaen Wei; Ruining Liu; Xiyun Hu; Tingen Liang; Zhiran Zhou; Zunnan Huang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-03       Impact factor: 4.553

3.  Fucoidan functionalization on poly(vinyl alcohol) hydrogels for improved endothelialization and hemocompatibility.

Authors:  Yuan Yao; Aung Moe Zaw; Deirdre E J Anderson; Monica T Hinds; Evelyn K F Yim
Journal:  Biomaterials       Date:  2020-04-01       Impact factor: 12.479

4.  Biological effects of fucoidan isolated from Fucus vesiculosus on thrombosis and vascular cells.

Authors:  Kyu-Won Kwak; Kil-Sang Cho; Ok-Jin Hahn; Kwang-Hyung Lee; Boo-Yong Lee; Jung-Jae Ko; Kwang-Hoe Chung
Journal:  Korean J Hematol       Date:  2010-03-31

5.  Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2).

Authors:  Bhanu Kanth Manne; Todd M Getz; Craig E Hughes; Osama Alshehri; Carol Dangelmaier; Ulhas P Naik; Steve P Watson; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

6.  Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways.

Authors:  Yong-Seok Han; Jun Hee Lee; Sang Hun Lee
Journal:  Mol Med Rep       Date:  2015-05-21       Impact factor: 2.952

7.  Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways.

Authors:  Hyunkyoung Lee; Jong-Shu Kim; Euikyung Kim
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

8.  The anticancer effect of fucoidan in PC-3 prostate cancer cells.

Authors:  Hye-Jin Boo; Ji-Young Hong; Sang-Cheol Kim; Jung-Il Kang; Min-Kyoung Kim; Eun-Ji Kim; Jin-Won Hyun; Young-Sang Koh; Eun-Sook Yoo; Jung-Mi Kwon; Hee-Kyoung Kang
Journal:  Mar Drugs       Date:  2013-08-19       Impact factor: 5.118

Review 9.  Therapies from Fucoidan: An Update.

Authors:  Janet Helen Fitton; Damien N Stringer; Samuel S Karpiniec
Journal:  Mar Drugs       Date:  2015-09-16       Impact factor: 5.118

10.  The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines.

Authors:  Eun-Young Min; In-Hye Kim; Jungim Lee; Eun-Young Kim; Youn-Hee Choi; Taek-Jeong Nam
Journal:  Int J Oncol       Date:  2014-05-08       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.